Philippe STEG, MD
Affiliations
- Chief, Department of Cardiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, in Paris, France.
- Vice President (in charge of research) of the board of the Assistance Publique-Hôpitaux de Paris network since 2018.
- Professor of Cardiology at Université Paris – Diderot (now Université de Paris), since 1994.
- Visiting Professor, Imperial College, London, UK
- Director of the “Clinical Research in Atherothrombosis” Research Team, INSERM Unit U1148, Paris
- Coordinator of the iVASC (InnoVations in Atherothrombosis SCience) RHU research consortium 2017-2021.
- Chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic research network since 2013.
- Chairman of the French National University Council (Conseil National des Universités) for Cardiology since 2016.
Honors
Dr Steg received the silver medal of the European Society of Cardiology in 2011, the Joseph A Vita Award from the American Heart Association in 2019 and the Grand Prix Claude Bernard de la Ville de Paris in 2019.
Research
Dr Steg has accumulated experience as a clinical trialist in the field of coronary artery disease, diabetes and antithrombotics. He is currently leading several large phase III clinical trials or international registries.
Publications
Dr Steg has authored > 1700 articles in peer-reviewed international journals. His H-Index is 135 (Web of Science) and he has > 115 000 citations. He has been a Thomson Reuters/Clarivate Analytics ”highly cited researcher” in Clinical Medicine every year since 2014. He is Senior Associate Editor for Circulation.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ServierTopic:CLARIFY registryDate added:04/13/2022Date updated:04/13/2022Relationship end date:01/01/2021
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AmarinTopic:REDUCE IT trialDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstraZenecaTopic:Atherosclerosis researchDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AmgenTopic:ConsultingDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NovartisTopic:Chair Victorion 2P trialDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenTopic:Chair Milvexian ACS trialDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Novo NordiskTopic:Consulting and speakingDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SanofiTopic:Consulting and speakingDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:KOWATopic:Steering Committee PROMINENT trialDate added:04/13/2022Date updated:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:LEXICONTopic:Chair SCORED trialDate added:04/13/2022Date updated:04/13/2022
Pages
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.